Business Context and Reporting Period
Company: Schering-Plough Corporation (Note: Input metadata referenced Merck & Co., Inc., but the filing text is for Schering-Plough Corporation).
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 1994.
Common Shares Outstanding: 192,039,778 as of June 30, 1994.
Key Financial Metrics
| Metric (Dollars in Millions) | 3 Months Ended 6/30/94 | 6 Months Ended 6/30/94 | 6 Months Ended 6/30/93 |
|---|---|---|---|
| Sales | $1,190.1 | $2,351.7 | $2,213.0 |
| Net Income | $240.7 | $493.9 | $342.5 |
| EPS (Diluted) | $1.25 | $2.56 | $1.74 |
| Operating Cash Flow (6mo) | N/A | $420.2 | $219.6 |
| Net Debt Position | N/A | $832.8 | $824.3 (Year-end 1993) |
| Cash & Cash Equivalents | $100.7 | $100.7 | $222.2 (Year-end 1993) |
Margins (6 Months 1994):
- Income before taxes: 27.6% of sales (vs. 25.8% in 1993).
- Cost of sales: 21.0% of sales (vs. 21.3% in 1993).
- Selling, general and administrative: 38.4% of sales (vs. 39.8% in 1993).
- Research and development: 12.5% of sales (vs. 12.7% in 1993).
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales increased 6% year-over-year for both the quarter and six-month period. Excluding foreign currency effects, sales grew 7%.
- Profitability: Net income rose 13% for the quarter and 44% for the six months. The six-month increase was significantly aided by a one-time cumulative effect of an accounting change in 1993 ($94.2 million charge) which did not recur in 1994.
- Product Performance:
- Domestic: Prescription pharmaceutical sales up 23% (quarter) and 19% (six months), driven by CLARITIN (respiratory) and EULEXIN (prostate cancer).
- International: Sales were flat for the quarter but up 3% for six months excluding currency. Significant declines in Japan (INTRON A down ~50%) were offset by growth in other regions.
- Health Care: Sales declined 9% (quarter) and 7% (six months) due to competitive pressure in female health and allergy/cold categories.
- Balance Sheet: Cash and cash equivalents decreased from $222.2 million to $100.7 million. Total debt declined $206.7 million, but net debt remained essentially flat due to share repurchases and dividends.
Guidance, Outlook, and Risks
- Health Care Reform: Management notes uncertainty regarding U.S. health care reform proposals (Medicare outpatient drug coverage, rebates) and international cost-containment programs. The impact on future operations and cash flows cannot be reasonably estimated.
- Tax Impact: The Omnibus Budget Reconciliation Act of 1993 increased the effective tax rate to 24.0% in 1994. Management estimates an additional unfavorable impact of 1.5 to 2.0 percentage points by 1996.
- Generic Competition: Generic entries for PROVENTIL (albuterol) are expected in late 1994 or early 1995, which will negatively affect sales and profitability.
- Japan Market: Sales of INTRON A in Japan are expected to remain substantially lower than 1993 levels due to government-mandated price cuts.
- Share Repurchases: The $500 million share repurchase program authorized in 1993 was approximately 98% complete as of June 30, 1994.
Investor Verification Checklist
- Verify the specific impact of the 1993 accounting change (SFAS No. 106) on the year-over-year net income comparison.
- Confirm the timeline and potential volume of generic competition for PROVENTIL and its effect on respiratory product margins.
- Monitor the final legislation of U.S. health care reform and its specific impact on prescription drug pricing and Medicare coverage.
- Assess the sustainability of sales growth in international markets excluding Japan, given the sharp decline in INTRON A sales.
- Review the projected increase in the effective tax rate through 1996 as outlined in management commentary.